FDA warned Duoc Thao Tre Xanh that its four herbal products are unapproved new drugs based on website disease claims.
What happened
FDA reviewed the company's website from October to December 2020 and found it took orders for Immune Health, Ganoderma Lucidum Red Reishi Mushroom, Papaya Leaf Extract and Fucoidan. The site claimed these products treat or prevent diseases such as cancer, diabetes, HIV, hepatitis and COVID-19. FDA said those claims make the products drugs, and because they are not FDA-approved they are unapproved new drugs (products needing FDA approval before sale) and are misbranded (not properly labeled with adequate directions for use).
What FDA found
Website claims show the four products are intended to cure, mitigate, treat or prevent disease, which makes them drugs under the law.
FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]The products are unapproved new drugs because FDA has not found them generally safe and effective for these uses and has not approved them.
FD&C Act sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]The products are misbranded because they lack adequate directions for use by a layperson for diseases that need a licensed practitioner's care.
FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Immune Health was marketed with claims to help against coronavirus/COVID-19 without FDA approval or authorization, and FDA asked for immediate removal of such sales.
FD&C Act sections 201(p), 505(a) [21 U.S.C. 321(p), 355(a)]
What FDA wants
FDA tells the company to take immediate action to stop selling unapproved products claimed for COVID-19 and to correct the cited violations. Within 15 working days, the company must notify FDA in writing of steps taken, with documentation, or explain any delay and when corrections will be complete.
Who should pay attention
- supplement brands and importers selling herbal products
- e-commerce sites that host product health claims
- regulatory teams reviewing websites and labels
This is a summary. Read the original letter on fda.gov.